Evidence map›Paper›PMID 25379943›Full record

ArticlePloS one2014

Comparative proteomics analysis of gastric cancer stem cells.

Tamami Morisaki, Masakazu Yashiro, Anna Kakehashi, Azusa Inagaki, Haruhito Kinoshita, Tatsunari Fukuoka, Hiroaki Kasashima, Go Masuda, Katsunobu Sakurai, Naoshi Kubo and 4 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 46 citations in OpenAlex.

  1. A Comprehensive Understanding ofCurrent issues in molecular biology · 2026
    Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. iScience · 2021
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Tamami MorisakiDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masakazu YashiroDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan; Oncology Institute of Geriatrics and Medical Science, Osaka City University Graduate School of Medicine, Osaka, Japan.
Anna KakehashiDepartment of Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Azusa InagakiDepartment of Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Haruhito KinoshitaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Tatsunari FukuokaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Hiroaki KasashimaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Go MasudaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Katsunobu SakuraiDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Naoshi KuboDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Kazuya MugurumaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Masaichi OhiraDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Hideki WanibuchiDepartment of Pathology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Kosei HirakawaDepartment of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka, Japan.
Osaka City University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer stem cells (CSCs) are responsible for cancer progression, metastasis, and recurrence. To date, the specific markers of CSCs remain undiscovered. The aim of this study was to identify novel biomarkers of gastric CSCs for clinical diagnosis using proteomics technology. CSC-like SP cells, OCUM-12/SP cells, OCUM-2MD3/SP cells, and their parent OCUM-12 cells and OCUM-2MD3 cells were used in this study. Protein lysates from each cell line were analyzed using QSTAR Elite Liquid Chromatography with Tandem Mass Spectrometry, coupled with isobaric tags for relative and absolute quantitation technology. Candidate proteins detected by proteomics technology were validated by immunohistochemical analysis of 300 gastric cancers. Based on the results of LC-MS/MS, eight proteins, including RBBP6, GLG1, VPS13A, DCTPP1, HSPA9, HSPA4, ALDOA, and KRT18, were up-regulated in both OCUM-12/SP cells and OCUM-2MD3/SP cells when compared to their corresponding parent cells. RT-PCR analysis indicated that the expression level of RBBP6, HSPA4, DCTPP1, HSPA9, VPS13A, ALDOA, GLG1, and CK18 was high in OCUM-12/SP and OCUM-2MD3/SP, in compared with the control of parent OCUM-12 and OCUM-2MD3. These proteins were significantly associated with advanced invasion depth, lymph node metastasis, distant metastasis, or advanced clinical stage. RBBP6, DCTPP1, HSPA4, and ALDOA expression in particular were significantly associated with a poor prognosis in the 300 gastric cancer patients. RBBP6 was determined to be an independent prognostic factor. The motility-stimulating ability of OCUM-12/SP cells and OCUM-2MD3/SP cells was inhibited by RBBP6 siRNA. These findings might suggest that the eight proteins, RBBP6, GLG1, VPS13A, DCTPP1, HSPA9, HSPA4, ALDOA, and KRT18, utilizing comparative proteomics analysis, were perceived to be potential CSC markers of gastric cancer. Of the eight candidate proteins, RBBP6 was suggested to be a promising prognostic biomarker and a therapeutic target for gastric cancer.

Indexed as

ProteomicsAdultAgedAged, 80 and overBiomarkers, TumorCarrier ProteinsCell Line, TumorCell MovementDNA-Binding ProteinsFemaleHumansMaleMiddle AgedNeoplasm InvasivenessNeoplastic Stem CellsPrognosisBiomarkers, TumorCarrier ProteinsDNA-Binding ProteinsRBBP6 protein, humanRNA, Small InterferingUbiquitin-Protein Ligases

Identifiers

PMID25379943
PMCPMC4224387
OpenAlexW2068756510

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.